Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019

INTRODUCTION: Terminal complement amplification is hypothesized to be a key contributor to the clinical manifestations of severe coronavirus disease 2019 (COVID-19). Ravulizumab, a humanized monoclonal antibody that binds with high affinity to complement protein C5 and inhibits terminal complement a...

Descripción completa

Detalles Bibliográficos
Autores principales: McEneny-King, Alanna C., Monteleone, Jonathan P. R., Kazani, Shamsah D., Ortiz, Stephan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024938/
https://www.ncbi.nlm.nih.gov/pubmed/33826106
http://dx.doi.org/10.1007/s40121-021-00425-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024938/
https://www.ncbi.nlm.nih.gov/pubmed/33826106
http://dx.doi.org/10.1007/s40121-021-00425-7

Ejemplares similares